Lezing Natuurwetenschappelijk Gezelschap LeidenThursday, March 21, 2019
Niels Bohrweg 2, 2333 CA Leiden
Making tumours disappear by shining a light on them? This could be the future. By adding light-sensitive molecule groups to cancer medicines, their cancer-destructing effect can be switched on in specific areas of the body. The severe side-effects of chemotherapy would belong to the past.
In this lecture, chemist Sylvestre Bonnet will show how chemotherapeutics can be turned into body-friendly medicines, destroying only tumor cells by shining visible light on them. This could be the solution for inoperable tumours around the nerves or brain, or in the biliary tract.
Photoactivated chemotherapeutic (PACT) compounds are metal complexes: molecules that consist of a positively charged metal ion and one or more electron-rich organic molecules. Metal compounds are often very toxic and can therefore be used to combat cancer. However, these metal ions are not selective and destroy not only tumor cells, but also healthy tissue.
To tackle this problem, a light-sensitive protective molecule group is added to the metal complex. In the presence of blue, green, or red light, this groups detaches itself, making the metal toxic again. By only illuminating the tumour, the harmful effects of the metal complex are limited to the tumour. This is in essence chemotherapy and radiotherapy combined, but without the side-effects.
New approach for chemists
Research into PACTs has always focused on finding suitable chemical compounds and assessing their photochemistry. To develop medicines that will benefit cancer patients, chemists must radically change their research approach. Switching from conducting traditional chemical research to thinking like pharmacologists and oncologists. How can this paradigm shift be accomplished?
About Sylvestre Bonnet
Sylvestre Bonnet obtained his PhD degree on molecular machines at the University of Strasbourg, France in 2007. He then moved to The Netherlands as a postdoctoral fellow. After a year at Utrecht University where he obtained a Veni grant, he came to Leiden University. In 2012 he received a Vidi grant, followed by an ERC Starting Grant in 2013. Since three years he is an associate professor at the Leiden Institute for Chemistry. His expertise lies at the intersection of bioinorganic chemistry, photochemistry, cancer science, and liposome technologies. His current research interests are light-activated anticancer metallodrugs, photocatalysis, and liposome technologies.
For more information and registration
Participants to our events can be recorded on photo and/or video. The Leiden Bio Science Park organisation has the right to use these captured images for promotion purposes through its own website, social media or other publication channels. In case you do not approve your picture to be published, we kindly request you to inform us by e-mail: email@example.com.